<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00184951</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF 03.01</org_study_id>
    <nct_id>NCT00184951</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Rosuvastatin and Lopinavir/Ritonavir in HIV Patients</brief_title>
  <official_title>Pharmacodynamics and Pharmacokinetics of Combined Use of Rosuvastatin (Crestor) and Lopinavir/Ritonavir (Kaletra) in HIV-Infected Patients With Hyperlipidemia (ROSALKA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <brief_summary>
    <textblock>
      open-label, multiple dose, single-group, 12 week trial in HIV-infected patients with
      hyperlipidemia while using lopinavir/ritonavir; both male or female subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the effect of rosuvastatin on plasma lipids, lipoproteins, and endothelial
      function in HIV-infected patients on stable lopinavir/ritonavir therapy and to evaluate the
      safety of combined use of rosuvastatin and lopinavir/ritonavir. Also to determine the effect
      of lopinavir/ritonavir on the pharmacokinetics of rosuvastatin compared to historical
      controls an to determine the effect of rosuvastatin on the pk of lopinavir/ritonavir compared
      to historical controls and by intrapatient comparison.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetics on week 0,4,8 and 12</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluation of lipid lowering activity on week 0,4,8,12</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endothelial function will be measured at week 0 &amp; 12 (optional for patients from Leiden and Nijmegen)</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>HIV Infections</condition>
  <condition>Hyperlipidemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  use of lopinavir 400mg/ritonavir 100mg bid &gt; 3months

          -  HIV-1 RNA &lt;400cop/mL

          -  fasting total cholesterol &gt; 6.2mmol/L

        Exclusion Criteria:

          -  history of sensitivity/idiosyncrasy to the drug or compounds used

          -  history or current condition that might interfere with absorption,distribution
             metabolism or excretion

          -  pregnant or breast-feeding

          -  serum transaminase levels &gt;3 times upper limit of normal, creatinine clearance
             &lt;60ml/min

          -  fasting plasma triglycerides level &gt;8.0 mmol/L

          -  history of statin-related rhabdomyolysis or inheritable muscle diseases in family
             history

          -  clinical symptoms of myopathy or abnormal CK level

          -  change in antiretroviral medication within the 3 months immediately preceding first
             dose of rosuvastatin

          -  use of any statin or fibrate within 6 weeks immediately preceding first dose of
             rosuvastatin

          -  concomitant use of medications that interfere with rosuvastatin or lopinavir
             pharmacokinetics

          -  active hepatobiliary or hepatic disease

          -  hypothyroidism

          -  alcohol abuse

          -  japanese or chinese patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M. Burger, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cologne</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Leiden</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>October 21, 2008</last_update_submitted>
  <last_update_submitted_qc>October 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2008</last_update_posted>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

